ADVFN US – Market Content Editor
-
IonQ shares edge higher after forming quantum tech partnership with Emergence Quantum
IonQ (NYSE:IONQ) saw its stock climb 1.3% following news of a strategic partnership with Australia-based research firm Emergence Quantum aimed at advancing ion trap quantum computing technologies. The collaboration will focus on co-developing cutting-edge materials and electronics, particularly in designing and simulating application-specific integrated circuits (ASICs) for qubit control. Efforts will also be made to…
-
OFA Group shares jump after unveiling $100 million digital asset treasury
OFA Group (NASDAQ:OFAL) saw its stock surge 26.6% following the announcement of a $100 million digital asset treasury initiative, alongside the appointment of Bitwise Asset Management to oversee its cryptocurrency strategy. Fresh off celebrating its IPO with a Nasdaq closing bell event, the architecture and technology firm revealed that this digital asset treasury is part…
-
Avidity Biosciences shares climb after FDA grants Breakthrough Therapy designation
Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) rose 4% Wednesday following the announcement that its drug candidate, delpacibart zotadirsen (del-zota), has been awarded Breakthrough Therapy status by the U.S. Food and Drug Administration. The designation applies to del-zota for treating Duchenne muscular dystrophy (DMD) in patients with mutations eligible for exon 44 skipping. This FDA status…
-
U.S. Stocks Gain on U.S.-Japan Trade Deal Hopes; Tesla, Alphabet Earnings in Focus
U.S. equity markets climbed on Wednesday, buoyed by optimism surrounding a new trade agreement between the United States and Japan. Investors also turned their attention to upcoming earnings reports from tech heavyweights Tesla and Alphabet. As of 09:35 ET, the Dow Jones Industrial Average was up 245 points (0.6%), the S&P 500 gained 23 points…
-
Infosys Q2 results meet earnings forecasts while revenue exceeds expectations
Infosys Limited (NYSE:INFY), the global leader in digital services and consulting, reported second-quarter earnings in line with analyst estimates, while revenue outperformed projections, leading to a modest 0.2% increase in its share price after the announcement. The company posted earnings per share of $0.19 for the quarter, matching the consensus forecast. Revenue reached $4.94 billion,…
-
First Busey shares climb after Q2 earnings surpass forecasts
Shares of First Busey Corporation (NASDAQ:BUSE) rose 2.9% following the regional bank’s announcement of second-quarter earnings that beat analyst projections, largely driven by strong revenue growth after acquiring CrossFirst Bankshares (NASDAQ:CFB). The bank reported adjusted earnings of $0.63 per share, exceeding the $0.60 consensus estimate. Revenue reached $198.05 million, topping the forecasted $193.73 million and…
-
Amphenol shares climb 6% on robust IT datacom-driven Q2 results
Amphenol Corporation (NYSE:APH) saw its shares rise 6% after reporting second-quarter earnings that far surpassed analyst predictions, fueled by outstanding growth in its IT datacom segment. The company posted adjusted earnings per share of $0.81, outperforming the estimated $0.66 by 23%. Revenue surged to $5.7 billion, marking a 57% year-over-year increase and well exceeding the…
-
Anebulo Pharmaceuticals shares surge 80% after board approves plan to go private
Shares of Anebulo Pharmaceuticals (NASDAQ:ANEB) jumped 80% following the company’s announcement that its Board of Directors has approved a plan to take the clinical-stage pharmaceutical firm private through a reverse stock split, which would end its status as a public SEC reporting company. The company intends to execute a reverse stock split at a ratio…
-
Johnson & Johnson’s Darzalex approved in EU for high-risk smouldering myeloma
Johnson & Johnson (NYSE:JNJ) announced Wednesday that the European Commission has granted approval for its Darzalex subcutaneous formulation to be used as a monotherapy for adults diagnosed with high-risk smouldering multiple myeloma. This approval represents the first treatment option available for this patient group, addressing a significant unmet need in managing the asymptomatic, intermediate stage…
-
Freeport-McMoRan surpasses Q2 expectations with boosted copper sales
Freeport-McMoRan (NYSE:FCX) delivered second-quarter earnings and revenue results that outpaced Wall Street forecasts, driven by increased copper production and sales. Despite this, the company’s shares slipped 1% in premarket trading. The U.S.-based mining giant reported adjusted earnings of $0.54 per share, exceeding the average analyst estimate of $0.45. Revenue climbed to $7.58 billion from $5.74…